Khavinson short peptide bioregulator (brain-targeted)
A short synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator family researched for cognitive and central nervous system support.
| Class / type | Khavinson short peptide bioregulator (brain-targeted) |
|---|---|
| Category | Cognitive & Nootropic |
| Status (Jul 2026) | Research use only |
It is proposed to act as an epigenetic regulator that penetrates cells and neurons and modulates gene expression influencing neuronal function, antioxidant defense, and stress-response pathways.
Researched for cognitive function, neuroprotection, circadian and stress regulation, and age-related brain decline.
Russian research reports antioxidant and neuroprotective effects and improved cognitive markers in animal and observational models; short peptide reported as well tolerated.
Supporting evidence is largely Russian and preclinical, with a lack of rigorous Western clinical trials; human efficacy unproven; unregulated sourcing and purity concerns.
Users report subjective improvements in mental sharpness and sleep, but sentiment is anecdotal.
NOT FDA-approved and not recognized as a drug in the United States; available only as an unregulated research or supplement-grade compound.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.